ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

PR firm Ketchum serves two clients on Medicare issues: CMS and ASCO. HHS policy officials weren’t told about potential conflict, department spokesman says.

September 24, 2004

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999

NCCAM Trial Tests Electroacupuncture for Delayed Nausea.

June 14, 2002

NCAB Committee Urged to Seek Surgical Oncology Certification

June 14, 1985

Pittsburgh, Norris Win Bristol-Myers Unrestricted Grants

April 19, 1991

Hopkins to Commit Own Money for Junior Faculty Research

May 2, 1986